Respite20 mg

Respite is a proton pump inhibitor used for the following indications:

Established / FDA-approved uses

• Healing of erosive or ulcerative gastro-esophageal reflux disease (GERD)
• Maintenance of healing of erosive GERD
• Symptomatic, non-erosive GERD (treatment of heartburn)
• Short-term treatment of active duodenal ulcer
• Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome

Combination-therapy indication

• Helicobacter pylori eradication in patients with duodenal ulcer disease, used together with two antibiotics (e.g., amoxicillin and clarithromycin) as triple therapy — Respite alone is not effective for eradication and must not be used as monotherapy for this purpose.

Guideline-supported / commonly used off-label

• Healing of active benign gastric ulcer (supported by clinical guidelines and regional labeling, though formal FDA approval for this specific indication varies by product)
• Prevention of NSAID-associated gastric ulcers in at-risk patients

The decision to use Respite for any indication should be made by a qualified physician after clinical evaluation.

Each enteric-coated, delayed-release tablet of Rabeprazole Sodium contains 10 mg or 20 mg of rabeprazole sodium as the active ingredient. The delayed-release (enteric) coating protects the acid-labile active substance from degradation by gastric acid, allowing it to be released and absorbed in the small intestine. Tablets also contain standard pharmaceutical excipients (fillers, binders, and coating agents) that vary by manufacturer.

Respite is a substituted benzimidazole belonging to the proton pump inhibitor (PPI) class of gastric acid-suppressing medicines. It is used to treat conditions caused or worsened by excess stomach acid, such as GERD, peptic ulcer disease, and hypersecretory disorders. Respite is available as enteric-coated delayed-release tablets (commonly 10 mg and 20 mg) and, in some markets, as delayed-release sprinkle capsules for patients who have difficulty swallowing tablets. It works by irreversibly blocking the final common pathway of gastric acid secretion, providing potent and long-lasting acid suppression.

Proton Pump Inhibitor (PPI) / Gastric acid-reducing agent

Rabeprazole Sodium is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system (the "proton pump") at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the gastric mucosa, Rabeprazole Sodium is classified as a gastric acid-pump inhibitor that blocks the final step of acid production. The effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus.

Pharmacokinetics: After oral administration of the delayed-release formulation, Rabeprazole Sodium is absorbed in the small intestine, with peak plasma concentrations reached in about 2–5 hours; bioavailability is approximately 52%. It is extensively metabolized in the liver, partly via the cytochrome P450 (CYP) enzyme system, particularly CYP3A4 and, to a lesser degree, CYP2C19, into inactive metabolites. Because metabolism relies less heavily on CYP2C19 than some other PPIs, plasma levels of Rabeprazole Sodium are relatively less affected by CYP2C19 genetic polymorphism, though poor metabolizers can still show higher exposure. The elimination half-life is approximately 1–2 hours, but the duration of acid suppression is much longer because the drug binds irreversibly to the proton pump; new pump synthesis is required to restore acid secretion. Excretion is mainly renal, with a smaller fraction eliminated in feces.

Respite delayed-release tablets should be swallowed whole with water; they must not be chewed, crushed, or split, as this destroys the enteric coating that protects the medicine from stomach acid. Tablets may be taken with or without food, though taking the dose after the morning meal at a consistent time each day is commonly recommended. Delayed-release sprinkle capsules of Respite (where available), should be opened and the contents sprinkled onto a small amount of soft food or mixed with a small amount of liquid, taken immediately and within 15 minutes, without chewing the granules, generally about 30 minutes before a meal. Doses should not be doubled to make up for a missed dose; the missed dose should simply be taken as soon as remembered unless it is close to the next scheduled dose.

Respite has the following well-established, clinically significant drug interactions:

• Rilpivirine-containing HIV medicines: Contraindicated in combination — reduced gastric acidity from Respite significantly decreases rilpivirine absorption and effectiveness (see Contraindications).
• Atazanavir and certain other HIV protease inhibitors: Concomitant use is not recommended, as Respite substantially reduces plasma levels of these drugs, risking loss of antiretroviral efficacy.
• Warfarin: Increases in INR and prothrombin time have been reported with PPIs including Respite; monitoring of INR/PT is recommended, especially at initiation or discontinuation, to reduce bleeding risk.
• Methotrexate (high-dose): PPIs including Respite may elevate and prolong serum methotrexate levels, increasing toxicity risk; temporary discontinuation of Respite may be considered under physician guidance during high-dose methotrexate therapy.
• Drugs requiring an acidic stomach for absorption (e.g., ketoconazole, itraconazole, certain iron salts, erlotinib, mycophenolate mofetil): Absorption of these drugs may be reduced by the acid suppression caused by Respite, potentially reducing their effectiveness.
• Digoxin: Gastric acid suppression by Respite can increase digoxin absorption; monitoring for digoxin toxicity is advised.
• Clopidogrel: Unlike some other PPIs, Respite has minimal effect on the active metabolite of clopidogrel, and no dose adjustment is generally required, though clinical judgment should be used.

Patients should inform their physician or pharmacist of all medicines, supplements, and herbal products they are taking before starting Respite.

Common side effects of Respite (generally mild and transient) include:

• Headache
• Diarrhea or, less commonly, constipation
• Abdominal pain
• Nausea or vomiting
• Flatulence
• Dry mouth
• Pharyngitis and cold-like symptoms (in pediatric use)

In combination therapy for H. pylori eradication, diarrhea and taste disturbance are reported more frequently.

Less common but serious effects associated with Respite and other PPIs — including bone fracture with long-term high-dose use, hypomagnesemia, vitamin B12 deficiency, Clostridioides difficile-associated diarrhea, acute interstitial nephritis, and severe skin reactions — are discussed in Precautions and Warnings. Patients should seek prompt medical attention for severe or persistent symptoms, signs of allergic reaction, or unexplained diarrhea while taking Respite.

Pregnancy: Data on the use of Respite in human pregnancy are limited. Animal reproduction studies have not shown clear evidence of fetal harm at clinically relevant exposures, but adequate, well-controlled studies in pregnant women are lacking. Respite should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus. A physician should always be consulted before use in pregnancy.

Lactation: It is not definitively known whether Respite is excreted in human breast milk, although related compounds have been detected in animal milk. Caution is advised, and a physician should be consulted to weigh the benefits of treatment against the possible risk to a breastfeeding infant before using Respite while breastfeeding.

The following precautions apply to the use of Respite:

• Masking of gastric malignancy: Symptomatic response to Respite does not exclude the presence of gastric malignancy. Appropriate evaluation should be considered in patients with alarm symptoms (e.g., unintentional weight loss, recurrent vomiting, dysphagia, GI bleeding) or those with a poor response to therapy, particularly in older adults.
• Bone fracture: Long-term use, especially at high doses over one year or more, has been associated with an increased risk of hip, wrist, and spine fractures. Patients should use the lowest effective dose for the shortest duration appropriate to the condition.
• Hypomagnesemia: Prolonged use (generally beyond one year) may cause low magnesium levels, occasionally severe, which can present as seizures, arrhythmias, or muscle spasms. Monitoring may be considered for long-term therapy or when used with other drugs that lower magnesium (e.g., diuretics).
• Vitamin B12 deficiency: Reduced stomach acid from long-term (generally over 3 years) use of Respite may impair vitamin B12 absorption.
• Clostridioides difficile-associated diarrhea: PPIs including Respite may increase the risk of this infection, particularly in hospitalized patients; persistent diarrhea that does not improve should be evaluated promptly.
• Acute interstitial nephritis: This has been reported with Respite and may occur at any point during therapy; if it develops, Respite should be discontinued and appropriate care sought.
• Rebound acid hypersecretion: Stopping Respite after prolonged use may cause a temporary increase in acid-related symptoms; gradual dose tapering under physician guidance may be considered.
• Cutaneous and systemic lupus erythematosus: Rare cases have been reported with PPI use; new or worsening joint pain or characteristic rash should be reported to a physician.

See Interactions, Pregnancy and Lactation, and Use in Special Populations for related safety information.

Experience with overdosage of Respite is limited, and no specific antidote is known. In case of a suspected overdose, seek immediate medical attention or contact a poison control center right away. Treatment of overdose with Respite is supportive and symptomatic, based on clinical presentation; dialysis is not expected to be significantly useful given the drug's protein binding and metabolism. Do not attempt to manage a suspected overdose at home without professional medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: No dose adjustment of Respite is generally required in patients with renal impairment, including those on chronic hemodialysis, though clinical judgment should guide use in severe renal disease.

Hepatic impairment: No dose adjustment is generally needed for mild-to-moderate hepatic impairment. Respite has not been well studied in severe hepatic impairment, and caution with physician supervision is advised.

Elderly: No overall dose adjustment is required based on age alone, though elderly patients may be at higher risk for some PPI-associated adverse effects (e.g., fractures, hypomagnesemia); see Precautions and Warnings.

Pediatric patients: Use is more limited than in adults; see Pediatric Uses for approved age ranges and weight-based dosing.

Pregnancy and breastfeeding: See Pregnancy and Lactation for detailed guidance.

Duration of treatment with Respite depends on the indication: symptomatic GERD and duodenal ulcer healing are typically treated for up to 4 weeks; erosive/ulcerative GERD and gastric ulcer healing may require 4–8 weeks, occasionally extended; maintenance therapy for healed erosive GERD may continue long-term under physician supervision; H. pylori eradication combination therapy is given for 7 days; and Zollinger-Ellison syndrome or other hypersecretory conditions may require long-term, individualized treatment for as long as clinically indicated. Treatment duration should always be determined by the prescribing physician and not extended or shortened without medical advice.

Proton Pump Inhibitors (PPIs); Substituted benzimidazoles; Gastric acid suppressants / anti-secretory agents

Rabeprazole Sodium acts by irreversibly binding to and inhibiting the hydrogen-potassium ATPase (H+/K+-ATPase) enzyme — the "proton pump" — located on the secretory (luminal) surface of gastric parietal cell membranes. This enzyme catalyzes the final step in gastric acid secretion, exchanging hydrogen ions for potassium ions across the parietal cell membrane. By blocking this final common pathway, Rabeprazole Sodium suppresses both basal and stimulated gastric acid secretion regardless of the stimulating agent (histamine, gastrin, or acetylcholine), producing potent and sustained acid suppression until new proton pumps are synthesized by the cell.

C

The safety and effectiveness of Respite have been established for short-term treatment of symptomatic GERD in adolescents 12 years of age and older, using the same 20 mg once-daily adult dose for up to 8 weeks. For children 1 to 11 years of age, Respite may be used for short-term treatment of GERD at weight-based doses (5 mg daily if under 15 kg; 10 mg daily if 15 kg or more) for up to 12 weeks, under physician supervision. The safety and efficacy of Respite have not been established in children younger than 1 year of age, nor for indications other than GERD in the pediatric population (e.g., duodenal ulcer, H. pylori eradication, or hypersecretory conditions). Use in children should always be directed by a pediatrician, with attention to the lowest effective dose and shortest necessary duration.